p63

P63, a homolog of the tumor suppressor p53, has been discovered in basal cells inside the epithelial layers of several tissues, including the epidermis, cervix, urothelium, breast, and prostate. p63 was identified in the nuclei of the basal epithelium in normal prostate glands; however, it was absent in malignant prostate tumors. The p63 antibody is recognized as an effective marker for distinguishing benign from malignant prostate lesions, especially when utilized alongside high molecular weight cytokeratin markers and the prostate-specific marker AMACR (P504S). p63 has been demonstrated to be a sensitive biomarker for lung squamous cell carcinomas (SqCC), exhibiting claimed sensitivities ranging from 80% to 100% . The specificity for lung squamous cell carcinoma (SqCC) compared to lung adenocarcinoma (LADC) is reported to be roughly 70-90%, with positive p63 staining being detected in 10-30% of LADC patients. p63 has been detected in the myoepithelial cells of normal breast duct tissue. Studies have highlighted the use of p63 in a panel of immunohistochemical markers for evaluating breast lesions, owing to the distinct expression patterns of luminal compared to basal and myoepithelial markers.